EPIDAREX IS A TRANSATLANTIC VENTURE CAPITAL FIRM LED BY A DIVERSE TEAM OF EARLY-STAGE INVESTORS BUILDING BREAKTHROUGH LIFE SCIENCE COMPANIES IN EMERGING HUBS
We are trusted partners to our founders and co-investors. We use our deep scientific and industry networks to create exceptional value and shared success.
Epidarex builds the extraordinary.
Recent News
Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair
Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK: Harness Therapeutics, a biotechnology company focused on protein upregulation
Kynos Therapeutics Announces Positive Top Line Results From the First-In-Human Phase I Study of its KMO Inhibitor, KNS366, Demonstrating Safety, Tolerability and Target Engagement
Edinburgh, UK – Kynos Therapeutics Ltd, a clinical stage biotechnology company developing first-in-class small molecule kynurenine 3-monooxygenase (KMO) inhibitors for acute and chronic